These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 2837353)
21. Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease. Lemansky P; Bishop DF; Desnick RJ; Hasilik A; von Figura K J Biol Chem; 1987 Feb; 262(5):2062-5. PubMed ID: 3029062 [TBL] [Abstract][Full Text] [Related]
22. Establishment of immortalized Schwann cells from Fabry mice and their low uptake of recombinant alpha-galactosidase. Kawashima I; Watabe K; Tajima Y; Fukushige T; Kanzaki T; Kanekura T; Sugawara K; Ohyanagi N; Suzuki T; Togawa T; Sakuraba H J Hum Genet; 2007; 52(12):1018-1025. PubMed ID: 17965825 [TBL] [Abstract][Full Text] [Related]
23. A microtechnique for quantitative measurements of acid hydrolases in fibroblasts. Its application in diagnosis of Fabry disease and enzyme replacement studies. Hasholt L; Sørensen SA Clin Chim Acta; 1984 Sep; 142(2):257-61. PubMed ID: 6094040 [No Abstract] [Full Text] [Related]
24. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease. Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513 [TBL] [Abstract][Full Text] [Related]
25. Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells. Prabakaran T; Nielsen R; Satchell SC; Mathieson PW; Feldt-Rasmussen U; Sørensen SS; Christensen EI PLoS One; 2012; 7(6):e39975. PubMed ID: 22768187 [TBL] [Abstract][Full Text] [Related]
26. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Medin JA; Tudor M; Simovitch R; Quirk JM; Jacobson S; Murray GJ; Brady RO Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7917-22. PubMed ID: 8755577 [TBL] [Abstract][Full Text] [Related]
27. [Biochemical and pathological studies on a carrier of Fabry's disease manifesting bouts of pain in the extremities]. Katayama M; Kobayashi T; Ohnishi A; Goto I; Kuroiwa Y Rinsho Shinkeigaku; 1984 Jun; 24(6):575-80. PubMed ID: 6094070 [No Abstract] [Full Text] [Related]
28. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ; N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963 [TBL] [Abstract][Full Text] [Related]
29. Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery. Sakuraba H; Chiba Y; Kotani M; Kawashima I; Ohsawa M; Tajima Y; Takaoka Y; Jigami Y; Takahashi H; Hirai Y; Shimada T; Hashimoto Y; Ishii K; Kobayashi T; Watabe K; Fukushige T; Kanzaki T J Hum Genet; 2006; 51(4):341-352. PubMed ID: 16532254 [TBL] [Abstract][Full Text] [Related]
30. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212 [TBL] [Abstract][Full Text] [Related]
31. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Ohashi T; Iizuka S; Ida H; Eto Y Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533 [TBL] [Abstract][Full Text] [Related]
32. Detection of Fabry's disease heterozygotes by enzyme analysis in single fibroblasts after cell sorting. Jongkind JF; Verkerk A; Niermeijer MF Clin Genet; 1983 Apr; 23(4):261-6. PubMed ID: 6303650 [TBL] [Abstract][Full Text] [Related]
33. [Update on the treatment of Fabry's disease: pathophysiological concepts]. Politei JM Rev Neurol; 2010 Nov; 51(9):561-70. PubMed ID: 20979036 [TBL] [Abstract][Full Text] [Related]
34. Residual activity of alpha-galactosidase A in Fabry's disease. Romeo G; D'Urso M; Pisacane A; Blum E; De Falco A; Ruffilli A Biochem Genet; 1975 Oct; 13(9-10):615-28. PubMed ID: 812485 [TBL] [Abstract][Full Text] [Related]
36. Uptake of lysosomal enzymes by human fibroblasts: lack of uptake of fungal or plant glycosidases in comparison with a mammalian enzyme. Dooley KC; Applegarth DA J Inherit Metab Dis; 1980; 3(4):145-7. PubMed ID: 6787335 [TBL] [Abstract][Full Text] [Related]
37. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407 [TBL] [Abstract][Full Text] [Related]
38. Fabry's disease with partially deficient hydrolysis of ceramide trihexoside. Kobayashi T; Kira J; Shinnoh N; Goto I; Kuroiwa Y J Neurol Sci; 1985 Feb; 67(2):179-85. PubMed ID: 2984338 [TBL] [Abstract][Full Text] [Related]
39. Properties of immobilized fig alpha-galactosidase and effect on ceramide-3 content of plasma from patients with Fabry's disease. Schram AW; Hamers MN; Oldenbroek-Haverkamp E; Strijland A; de Jonge A; van den Bergh FA; Tager JM Biochim Biophys Acta; 1978 Dec; 527(2):456-64. PubMed ID: 31916 [TBL] [Abstract][Full Text] [Related]